Ersatta (mono-pegylated version of C-peptide) / Cebix - LARVOL DELTA

"@kristenhaase @shroderSattar @martine_puts @SPilleron @KenisCindy @FayStrohschein" (@mpergolottiPhD)

"6- (continued-sorry for omitions) J. Wang @Columbia @dentenberg M.Oktay J. Condeelis @EinsteinMed @effiken @luciaborriell @WilliamOhMD @veronicaalejc and the team @HiberCell V. Patel @TischCancer @AndrewEAplin @SilvioGutkind @gabyrabi @mariansalatino @rmperrotta @MaguerSattaLab" (@JAguirreGhiso)

Oncology

Cebix announces positive results of Ersatta phase 1/2 trial in peripheral neuropathy (Cebix) - P1/2, N=70; "The successful 72 subject trial, which focused on safety, tolerability, and pharmacokinetics, demonstrated that ERSATTA was well tolerated, with no serious adverse effects over a twelve week period. The pharmacokinetic profile supports convenient, once weekly dosing...Cebix is well-positioned to launch our Phase 2b trial in early Q1 2013"

Anticipated new P2 trial • P1/2 data • Pain